Drugdu.com expert's response:

Regorafenib tablets are multi-target tyrosine kinase inhibitors primarily used in the treatment of various solid tumors. They possess anti-angiogenic properties and can inhibit tumor cell proliferation and metastasis. Their specific efficacy includes:

I. Treatment of Gastrointestinal Stromal Tumors (GIST)

Patient Population: Patients with locally advanced, unresectable, or metastatic gastrointestinal stromal tumors who have experienced disease progression or intolerance after previous treatment with imatinib mesylate and sunitinib malate.

Mechanism of Action: By inhibiting targets such as KIT, PDGFRα, RET, and VEGFR, it blocks signal transduction pathways in tumor cells, inhibiting tumor growth and angiogenesis.

II. Treatment of Hepatocellular Carcinoma (HCC)

Patient Population: Patients with hepatocellular carcinoma who have previously received sorafenib treatment.

Mechanism of Action: Inhibits targets such as VEGFR, TIE2, PDGFR, and FGFR, reducing tumor angiogenesis and inhibiting tumor growth and spread.

III. Treatment of Metastatic Colorectal Cancer (mCRC)

Patient Population: Patients with metastatic colorectal cancer who have previously received fluorouracil-, oxaliplatin-, and irinotecan-based chemotherapy, as well as those who have received or are unsuitable for anti-VEGF or anti-EGFR (RAS wild-type) therapy.

Mechanism of Action: By inhibiting targets such as VEGFR, TIE2, PDGFR, FGFR, KIT, and RET, it blocks tumor angiogenesis and cell proliferation signaling pathways, inhibiting tumor growth and metastasis.

IV. Anti-Angiogenesis：Regorafenib tablets inhibit targets such as vascular endothelial growth factor receptors (VEGFR), platelet-derived growth factor receptors (PDGFR), and fibroblast growth factor receptors (FGFR), blocking tumor angiogenesis and reducing blood supply to the tumor, thereby inhibiting tumor growth.

V. Inhibition of Tumor Cell Proliferation and Metastasis：Regorafenib tablets inhibit targets such as KIT, RET, and BRAF, which are associated with tumor cell proliferation and survival, blocking signal transduction pathways in tumor cells and inhibiting their proliferation and metastasis.

VI. Modulation of the Tumor Microenvironment：Regorafenib tablets inhibit the recruitment and activation of tumor-associated macrophages (TAMs), reducing inflammatory responses in the tumor microenvironment and inhibiting tumor growth and metastasis.

VII. Extension of Patient Survival：In clinical trials, as a second- or third-line treatment, regorafenib tablets have significantly prolonged progression-free survival (PFS) and overall survival (OS) in patients with gastrointestinal stromal tumors, hepatocellular carcinoma, and metastatic colorectal cancer.

VIII. Improvement of Patient Quality of Life：Regorafenib tablets can alleviate tumor-related symptoms such as pain and fatigue, thereby improving patients' quality of life.

IX. Enhancement of Other Treatment Modalities：Regorafenib tablets may enhance the efficacy of other anticancer treatments (such as chemotherapy and radiotherapy) by influencing the tumor microenvironment.

X. Usage Precautions

Side Effects: Regorafenib tablets may cause side effects such as fatigue, loss of appetite, diarrhea, oral mucositis, weight loss, infections, hypertension, and hand-foot skin reactions (hand-foot syndrome). Severe side effects include liver injury and gastrointestinal perforation.

Monitoring: During treatment, regular monitoring of liver function, blood pressure, and other indicators is required to promptly manage adverse reactions.

Contraindications: Patients allergic to regorafenib or its components are prohibited from using it.